DE3843241A1 - Nephroprotektive infusionsloesung - Google Patents
Nephroprotektive infusionsloesungInfo
- Publication number
- DE3843241A1 DE3843241A1 DE3843241A DE3843241A DE3843241A1 DE 3843241 A1 DE3843241 A1 DE 3843241A1 DE 3843241 A DE3843241 A DE 3843241A DE 3843241 A DE3843241 A DE 3843241A DE 3843241 A1 DE3843241 A1 DE 3843241A1
- Authority
- DE
- Germany
- Prior art keywords
- amino acids
- mixture
- use according
- kidney
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001607 nephroprotective effect Effects 0.000 title description 4
- 239000003978 infusion fluid Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 210000003734 kidney Anatomy 0.000 claims abstract description 15
- 230000006378 damage Effects 0.000 claims abstract description 13
- 239000000824 cytostatic agent Substances 0.000 claims abstract description 9
- 231100000331 toxic Toxicity 0.000 claims abstract description 9
- 230000002588 toxic effect Effects 0.000 claims abstract description 9
- 230000001085 cytostatic effect Effects 0.000 claims abstract description 7
- 229940024606 amino acid Drugs 0.000 claims description 22
- 235000001014 amino acid Nutrition 0.000 claims description 20
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 230000007935 neutral effect Effects 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 229940009098 aspartate Drugs 0.000 claims description 3
- 238000011067 equilibration Methods 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003344 environmental pollutant Substances 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 231100000719 pollutant Toxicity 0.000 claims 1
- 150000008575 L-amino acids Chemical class 0.000 abstract description 12
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 229940124589 immunosuppressive drug Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 238000011835 investigation Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 210000003292 kidney cell Anatomy 0.000 description 5
- 230000002132 lysosomal effect Effects 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 4
- 230000013878 renal filtration Effects 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 230000004900 autophagic degradation Effects 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000003589 nefrotoxic effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010029155 Nephropathy toxic Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 231100000381 nephrotoxic Toxicity 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 230000007694 nephrotoxicity Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- -1 anionic amino acids Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000004937 luminal membrane Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100001210 nonnephrotoxic Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 210000005234 proximal tubule cell Anatomy 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008060 renal absorption Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 230000010245 tubular reabsorption Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3843241A DE3843241A1 (de) | 1988-12-22 | 1988-12-22 | Nephroprotektive infusionsloesung |
| SU894830956A RU2077883C1 (ru) | 1988-12-22 | 1989-12-21 | Композиция для внутривенного введения для защиты почек от токсического действия нефротоксичных цитостатических средств и иммуносупрессоров |
| PCT/DE1989/000780 WO1990006769A1 (de) | 1988-12-22 | 1989-12-21 | Nephroprotektive infusionslösung |
| JP2500961A JPH078790B2 (ja) | 1988-12-22 | 1989-12-21 | 腎保護持続注入液 |
| DE58908288T DE58908288D1 (de) | 1988-12-22 | 1989-12-21 | Nephroprotektive infusionslösung. |
| EP90900071A EP0408691B1 (de) | 1988-12-22 | 1989-12-21 | Nephroprotektive infusionslösung |
| AU48079/90A AU4807990A (en) | 1988-12-22 | 1989-12-21 | Antinephrotoxic perfusion solution |
| ES90900071T ES2063332T3 (es) | 1988-12-22 | 1989-12-21 | Solucion de infusion nefroprotectora. |
| AT90900071T ATE110570T1 (de) | 1988-12-22 | 1989-12-21 | Nephroprotektive infusionslösung. |
| US07/873,579 US5290538A (en) | 1988-12-22 | 1992-04-21 | Nephro protective infusion solutions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3843241A DE3843241A1 (de) | 1988-12-22 | 1988-12-22 | Nephroprotektive infusionsloesung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3843241A1 true DE3843241A1 (de) | 1990-06-28 |
| DE3843241C2 DE3843241C2 (enExample) | 1990-11-22 |
Family
ID=6369857
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3843241A Granted DE3843241A1 (de) | 1988-12-22 | 1988-12-22 | Nephroprotektive infusionsloesung |
| DE58908288T Expired - Fee Related DE58908288D1 (de) | 1988-12-22 | 1989-12-21 | Nephroprotektive infusionslösung. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE58908288T Expired - Fee Related DE58908288D1 (de) | 1988-12-22 | 1989-12-21 | Nephroprotektive infusionslösung. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0408691B1 (enExample) |
| JP (1) | JPH078790B2 (enExample) |
| AT (1) | ATE110570T1 (enExample) |
| AU (1) | AU4807990A (enExample) |
| DE (2) | DE3843241A1 (enExample) |
| ES (1) | ES2063332T3 (enExample) |
| RU (1) | RU2077883C1 (enExample) |
| WO (1) | WO1990006769A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6224776B1 (en) | 1996-05-24 | 2001-05-01 | Cultor Corporation | Method for fractionating a solution |
| US6096785A (en) * | 1996-07-30 | 2000-08-01 | Novartis Nutrition Ag | Amino acid compositions and use thereof in treating renal dysfunction |
| UA65587C2 (en) * | 1997-10-09 | 2004-04-15 | Baker Norton Pharma | Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus |
| NZ513926A (en) * | 1999-02-23 | 2001-09-28 | Univ California | Methods of treatment of mitochondrial disorders |
| FI20010977A7 (fi) | 2001-05-09 | 2002-11-10 | Danisco Sweeteners Oy | Kromatografinen erotusmenetelmä |
| PL206018B1 (pl) | 2001-10-19 | 2010-06-30 | Isotechnika Inc | Preparat farmaceutyczny, sposób jego wytwarzania, mikroemulsja i zastosowanie tego preparatu farmaceutycznego |
| JPWO2005094813A1 (ja) * | 2004-03-31 | 2008-02-14 | 味の素株式会社 | 腎疾患用薬剤 |
| US9669010B2 (en) | 2012-12-06 | 2017-06-06 | Bio Health Solutions, Llc | Treatment for chronic kidney disease |
| EP2928461B1 (en) * | 2012-12-06 | 2019-08-21 | Bio Health Solutions, LLC | Treatment for chronic kidney disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3414491A1 (de) * | 1984-04-17 | 1985-10-24 | Hans Dr. 8202 Bad Aibling Dietl | L-aminosaeurengemische fuer die parenterale und orale anwendung bei nierenerkrankungen |
-
1988
- 1988-12-22 DE DE3843241A patent/DE3843241A1/de active Granted
-
1989
- 1989-12-21 RU SU894830956A patent/RU2077883C1/ru active
- 1989-12-21 EP EP90900071A patent/EP0408691B1/de not_active Expired - Lifetime
- 1989-12-21 ES ES90900071T patent/ES2063332T3/es not_active Expired - Lifetime
- 1989-12-21 WO PCT/DE1989/000780 patent/WO1990006769A1/de not_active Ceased
- 1989-12-21 JP JP2500961A patent/JPH078790B2/ja not_active Expired - Lifetime
- 1989-12-21 DE DE58908288T patent/DE58908288D1/de not_active Expired - Fee Related
- 1989-12-21 AU AU48079/90A patent/AU4807990A/en not_active Abandoned
- 1989-12-21 AT AT90900071T patent/ATE110570T1/de not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3414491A1 (de) * | 1984-04-17 | 1985-10-24 | Hans Dr. 8202 Bad Aibling Dietl | L-aminosaeurengemische fuer die parenterale und orale anwendung bei nierenerkrankungen |
Non-Patent Citations (1)
| Title |
|---|
| CA 98, 1983:88032u, ZAGER, R.A. et al.: J. Lab. Clin. Med., 1983, 101, S. 130-140 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH03502805A (ja) | 1991-06-27 |
| ES2063332T3 (es) | 1995-01-01 |
| AU4807990A (en) | 1990-07-10 |
| EP0408691B1 (de) | 1994-08-31 |
| ATE110570T1 (de) | 1994-09-15 |
| DE3843241C2 (enExample) | 1990-11-22 |
| RU2077883C1 (ru) | 1997-04-27 |
| EP0408691A1 (de) | 1991-01-23 |
| WO1990006769A1 (de) | 1990-06-28 |
| JPH078790B2 (ja) | 1995-02-01 |
| DE58908288D1 (de) | 1994-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69533940T2 (de) | Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren | |
| DE69527660T2 (de) | Osmotisches Mittel für die Peritonealdialyse | |
| DE69928410T2 (de) | Selenium enthaltende zusammensetzung zur behandlung von systemischen entzündungssyndromen | |
| DE69028712T2 (de) | Zusammensetzung zur behandlung entzündlicher darmerkrankungen | |
| DE69127087T2 (de) | Wachstumsfaktor und glutamin enthaltendes produkt und verwendung des wachstumsfaktors zur behandlung der darmschleimhaut | |
| CH642541A5 (de) | Essentielle aminosaeuren enthaltende loesung zur verabreichung an krebspatienten. | |
| DE3650620T2 (de) | Behandlungsverfahren kataboler dysfunktion | |
| DE3026180C2 (de) | Rifamycin-SV-Salze von basischen Aminosäuren, Verfahren zu ihrer Herstellung und Arzneimittel zur intraartikulären Injektion bei der Bekämpfung von rheumatoider Arthritis | |
| DE2921312A1 (de) | Pharmazeutisches mittel und dessen verwendung bei einer vollstaendig parenteralen ernaehrung | |
| DE69331465T2 (de) | Intravenöse lösung, die den protein - und wasserverlust im körper reduziert | |
| DE3843241A1 (de) | Nephroprotektive infusionsloesung | |
| DE69220821T2 (de) | Verfahren zur Sicherstellung eines angemessenen intrazellulären Glutathionspiegels im Gewebe | |
| DE3115080C2 (de) | Arzneimittel enthaltend Cytidindiphosphocholin und Lecithin | |
| DE2326600C2 (enExample) | ||
| EP0370994B1 (de) | Behandlung von durch Glucose ausgelöster Quervernetzung von Collagen bei Diabetes mellitus-Patienten durch Arginin, Spermidin, Kreatin oder Agmatin | |
| DE2554453A1 (de) | Medikament zur glykaemieregulierung | |
| DE2750159C3 (de) | Infusionslösung zur Behandlung von hepatischer Encephalopathie und ein Verfahren zu deren Herstellung | |
| EP0083439A2 (de) | 4-Sulfido-oxazaphosphorine und deren Verwendung bei der Krebsbekämpfung und zur Immunsuppression | |
| DE2516027A1 (de) | Arzneimittel zur foerderung der proteinsynthese und zur konservierung des stickstoffs im koerper | |
| DE2944341A1 (de) | Aminosaeuren enthaltendes pharmazeutisches praeparat | |
| DE68901656T2 (de) | Pharmazeutische zusammensetzung zur milderung der nebenwirkungen von platinhaltigen arzneimitteln. | |
| DE1805257A1 (de) | Diagnostische Zubereitung und Verfahren zu deren Herstellung | |
| EP0401347B1 (de) | Verwendung von transferrin zur bekämpfung der toxischen wirkung des endotoxins bei der endotoxinämie | |
| EP0013962A1 (de) | Aminosäuren und Mineralsalze enthaltende Infusionslösung | |
| WO1998038994A2 (de) | Kombinationspräparat aus 2-methylthiazolidin-2,4-dicarbonsäure und paracetamol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |